NCT06725888View on ClinicalTrials.gov

Evaluation of the Medical Device Vagitab - T as Adjuvant Therapy in Patients With Bacterial Vaginosis.

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

September 23, 2025

Study Completion Date

September 30, 2025

Conditions
Bacterial Vaginosis (BV)Recurrent Bacterial Vaginosis
Interventions
DEVICE

Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:

"Vagitab -T will be used for 3 monthly cycles of 10 days each. Metronidazole will be used for 1 cycle of 7 days at the start of the study~Metronidazole will be administered as follows:~500 mg intravaginally once per day for 7 days or 500 mg orally 2 times/day for 7 days"

Trial Locations (1)

300006

RECRUITING

Gyniclinique - Strada Johann Wolfgang von Goethe nr. 2, Timișoara

All Listed Sponsors
collaborator

Opera CRO, a TIGERMED Group Company

OTHER

lead

S.I.I.T. Srl

INDUSTRY